Potential impact of a delayed ADAMTS13 result in the treatment of thrombotic microangiopathy: an economic analysis

Abstract

In patients with clinical presentations of TMAs, having a rapid TAT for pre-exchange ADAMTS13 measurement appeared to be cost-effective. If testing cannot be performed in-house, then our findings support the necessity of contracting with a reference laboratory that can reliably provide the result, preferably within 1 day of admission.